This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
dexamethasone
Dexamethasone
Potent synthetic glucocorticoid (25× cortisol potency); GR-mediated genomic suppression of NF-κB/AP-1 → ↓ IL-1/6/8/TNF. Zero mineralocorticoid activity. RECOVERY trial: 17% mortality ↓ in severe COVID-19. Also used for cerebral edema, anaphylaxis, adrenal crisis, antiemesis.
Entry Metadata
| Field | Value |
|---|---|
| ID | dexamethasone |
| Name | Dexamethasone |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Stream | 01-modern |
Cross-Atlas Connections
Sources
- RECOVERY Collaborative Group; Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. · PubMed 32678530
- Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42-54. · PubMed 29162310
- Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-23. · PubMed 16236742
- Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors. Neurology. 1994;44(4):675-80. · PubMed 8164826